Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MK-7684A with or without docetaxel versus docetaxel in metastatic non-small cell lung cancer after platinum chemotherapy and prior PD-1/PD-L1 immunotherapy
MOH_2021-04-13_009764Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing MK-7684A + docetaxel, MK-7684A and placebo + docetaxel (3 arms). Primary endpoint: Progression-free survival. Started Feb 2021; status: completed.
02
Drugs
vibostolimab + pembrolizumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2021-04-13_009764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-13_009764.